Doris Matsui (D-CA)
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
A Democratic bill with 1 Republican cosponsor · See all 2 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The "Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026" amends the Social Security Act regarding Medicare part D prescription drug plans. Starting January 1, 2027, it requires plan sponsors using a formulary to place certain generic drugs and at least two biosimilar biological products in a preferred position if their wholesale acquisition cost is lower than the reference product. It also prohibits plan sponsors from placing more restrictive access limits on these lower-cost options than those placed on the reference drugs.
Yes· 3 of 17
- Scored +9
Would people over 65 be better off under this?
Directly targets Medicare Part D enrollees by reducing their out-of-pocket prescription drug costs.
- Scored +9
Would retired people be better off under this?
Directly benefits retirees who utilize Medicare Part D for prescription drug coverage.
- Scored +8
Does this lower the price of prescription medicines?
Directly mandates the preferred placement of lower-cost generics and biosimilars to reduce patient out-of-pocket costs.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Lower Out-of-Pocket Costs: By requiring generic drugs and biosimilar biological products with lower wholesale acquisition costs to be in a "preferred position," patients would have lower out-of-pocket costs compared to reference drugs (Section 2, subparagraph (J)(i) and (iii)(III)).
-
Increased Access to Lower-Cost Options: The bill prevents plan sponsors from using restrictive techniques like step therapy or prior authorization on these generic and biosimilar products if those limits are more restrictive than those for the reference drug (Section 2, subparagraph (J)(ii)).
Potential Negative Impacts for People
- No negative impacts for people are explicitly mentioned in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would retired people be better off under this? — Directly benefits retirees who utilize Medicare Part D for prescription drug coverage. Would people over 65 be better off under this? — Directly targets Medicare Part D enrollees by reducing their out-of-pocket prescription drug costs. Would households on low incomes be better off under this? — Low-income seniors will benefit significantly from reduced out-of-pocket costs for essential medications. Would middle-income households be better off under this? — Provides cost savings for middle-class seniors using Medicare Part D. Would people with disabilities be better off under this? — Many people with disabilities use Medicare and will benefit from lower drug costs. Would Black Americans be better off under this? — Positive impact via improved medication affordability for senior citizens in this demographic. Would Asian Americans be better off under this? — Positive impact via improved medication affordability for senior citizens in this demographic. Would Hispanic Americans be better off under this? — Positive impact via improved medication affordability for senior citizens in this demographic. Would Native Americans be better off under this? — Positive impact via improved medication affordability for senior citizens in this demographic. Would veterans be better off under this, taking everything together? — Veterans who rely on Medicare Part D for certain medications will see reduced costs. Would white Americans be better off under this? — Positive impact via improved medication affordability for senior citizens in this demographic. Would high-income households be better off under this? — Provides some cost savings, though the impact is less significant than for lower-income groups.
- Healthcare
- Does this lower the price of prescription medicines? — Directly mandates the preferred placement of lower-cost generics and biosimilars to reduce patient out-of-pocket costs. Does this make health care easier to get in general? — Improves access by prohibiting more restrictive access limits on lower-cost generics than on reference drugs.
- Economy And Finance
- Does this give people more protection from unfair business practices? — Increases consumer access to lower-cost medication options by restricting restrictive formulary practices.
- Governance And Ideology
- Does this give the federal government more power? — Increases federal mandates on how Medicare Part D plan sponsors manage their formularies.
- Social Issues And Justice
- Is this likely to lift people out of poverty? — Reduces the financial burden of healthcare for seniors, which can indirectly reduce poverty levels among fixed-income populations.
- 3/27/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2 Cosponsors added.
- Introduced in House
Jake AuchinclossDemocrat · Massachusetts
Mariannette Miller-MeeksRepublican · Iowa